Bipolar depression study scrapped before it began

NCT ID NCT05060549

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to explore how cariprazine (Vraylar) might help people with bipolar depression by looking at its effect on a specific brain receptor (D3 dopamine). Participants would have taken cariprazine for six weeks and undergone PET scans to see how the drug works in the brain. However, the study was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

cariprazine (Vraylar)

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE EPISODE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar depression bipolar disorder bipolar I disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States